Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Associations of CYP19A1 and ESR1 genotypes with analysis endpoints

From: Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

    Univariate model Multivariableb model Multivariablec model
Gene: SNP Comparisons Numbera (events) Odds ratio (95 % CI) P value Odds ratio (95 % CI) P value Odds ratio (95 % CI) P value
Hot flashes/sweating
CYP19A1: rs4646 Dose effectd 1965 (848) 1.05 (0.91,1.21) 0.50 1.04 (0.90,1.20) 0.63 1.08 (0.93,1.25) 0.30
CYP19A1: rs10046 T/T vs. C/T,C/C (ref) 446 (172) vs. 1519 (676) 0.78 (0.63,0.97) 0.03 0.82 (0.66,1.02) 0.08 0.83 (0.66,1.04) 0.10
ESR1:rs2077647 Dose effect 1965 (848) 0.95 (0.84,1.08) 0.47 0.96 (0.84,1.09) 0.51 0.97 (0.85,1.11) 0.69
ESR1:rs2234693 (PvuII) Dose effect 1965 (848) 0.92 (0.80,1.04) 0.18 0.92 (0.80,1.04) 0.19 0.94 (0.82,1.07) 0.36
ESR1:rs9340799 (XbaI) Dose effect 1965 (848) 0.94 (0.82,1.08) 0.38 0.94 (0.82,1.07) 0.34 0.98 (0.85,1.12) 0.73
Musculoskeletal symptoms
CYP19A1: rs4646 Dose effectd 1966 (516) 1.01 (0.86,1.18) 0.90 1.05 (0.89,1.24) 0.55 1.11 (0.93,1.31) 0.25
CYP19A1: rs10046 T/T vs. C/T,C/C (ref) 446 (110) vs. 1520 (406) 0.90 (0.70,1.15) 0.39 0.86 (0.66,1.10) 0.23 0.84 (0.65,1.09) 0.18
ESR1:rs2077647 Dose effect 1966 (516) 1.08 (0.94,1.25) 0.28 1.12 (0.96,1.30) 0.15 1.11 (0.95,1.29) 0.20
ESR1:rs2234693 (PvuII) Dose effect 1966 (516) 1.03 (0.90,1.19) 0.65 1.07 (0.92,1.25) 0.37 1.06 (0.91,1.24) 0.47
ESR1:rs9340799 (XbaI) Dose effect 1966 (516) 1.06 (0.91,1.23) 0.44 1.10 (0.94,1.29) 0.22 1.11 (0.94,1.30) 0.22
  1. Analysis endpoints were early-onset (within 6 months) grade ≥2 hot flashes/sweating or (within 12 months) grade ≥2 musculoskeletal symptoms. aPatients without any adverse event data, excluded from analyses (2 without hot flashes/sweating and one without musculoskeletal symptoms). bMultivariable logistic regression model adjusted for characteristics: age, menstruation status, BMI, adjuvant chemotherapy use, treatment assignment, and presence of hot flashes/sweating at baseline or of musculoskeletal symptoms at baseline (according to endpoint). cMultivariable model also adjusted for relevant concomitant medications prior to or continuing at baseline, and use during relevant time period for the endpoint. dDose effect: comparisons of variant (Var) allele groups: 0 (Var) vs. 1 (Var) vs. 2 (Var). SNP single nucleotide polymorphism